Edit
Orion Biotechnology Canada, Ltd.
https://orionbiotechnology.com/Last activity: 06.03.2024
Active
CONTACT US Unlocking the Therapeutic Potential of Complex GPCRs Our People Our Science Orion Biotechnology is a clinical stage company discovering and developing next-generation G Protein-Coupled Receptor (GPCR)-targeted therapeutics for the treatment of cancer and other serious diseases. Orion’s novel drug modality involves precision engineering ligands of peptide and protein GPCRs to develop analogs with ... Read moreHome
Location: Canada, Ontario, Ottawa
Investors 2
| Date | Name | Website |
| - | K2X | k2x.capita... |
| - | Cantilever... | cantilever... |
Mentions in press and media 5
| Date | Title | Description |
| 06.03.2024 | Orion Biotechnology Presenting at the 3rd GPCR-Targeted Drug Discovery Summit in Boston | - |
| 16.12.2021 | Evofem Biosciences and Orion Biotechnology Launch Collaboration to Develop MPT Product Candidate to Include HIV Prevention | SAN DIEGO, Dec. 16, 2021 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ: EVFM) and Orion Biotechnology Canada Ltd. today announced that they have entered into a collaboration agreement to evaluate the compatibility and stability of Orion'... |
| 23.11.2021 | Keiretsu Forum Held Largest Investor Gathering to Showcase 21 Innovative Growth-Stage Companies Actively Seeking Funding | Over 1,700 registered investors, more than 1,900 expressions of interest, 6 Most Valued Company winners and an extensive panel of subject matter experts make the 2021 EXPO a rousing success PHILADELPHIA, Nov. 23, 2021 (GLOBE NEWSWIRE) -- Mo... |
| 17.06.2021 | ORION BIOTECHNOLOGY SECURES $11.5M SERIES A FINANCING | ottawa, canada, June 17, 2021 (GLOBE NEWSWIRE) -- Orion Biotechnology Canada Ltd., a clinical-stage biotechnology company, today announced that it has raised $11.5M USD in a Series A financing. The oversubscribed round was led by Keiretsu F... |
| - | Orion Biotechnology | “CONTACT US Unlocking the Therapeutic Potential of Previously Undruggable GPCRs Our People Our Science Orion Biotechnology is discovering and developing G Protein-Coupled Receptor (GPCR) targeted therapies to treat metabolic and immunologic... |